Showing 6311-6320 of 9998 results for "".
- Amgen/Kyowa Kirin's Anti-OX40 Shows Efficacy in Phase 2 for ADhttps://practicaldermatology.com/news/amgenkyowa-kirins-anti-ox40-shows-efficacy-in-phase-2-for-ad/2460943/Positive data from a Phase 2 study of AMG 451/KHK4083, presented at the European Academy of Dermatology and Venereology 30th Virtual Congress, show that the potential first-in-class anti-OX40 fully human monoclonal antibody in development for the treatment of moderate-to-severe atopic d
- Arcutis Submits NDA for Topical Roflumilast Cream for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-submits-npa-for-topical-roflumilast-cream-for-plaque-psoriasis/2460942/
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented
- Castle Creek, Mayo Clinic to Collaborate on Therapies for Rare Genetic Connective Tissue Disordershttps://practicaldermatology.com/news/castle-creek-mayo-clinic-to-collaborate-on-therapies-for-rare-genetic-connective-tissue-disorders/2460930/Castle Creek Biosciences, Inc. is collaborating with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of osteogenesis imperfecta (OI) and classical Ehlers-Danlos syndrome (EDS). Neither rare genetic connective tissue disord
- Science of Skincare Summit Coming in Novemberhttps://practicaldermatology.com/news/science-of-skincare-summit-coming-in-november/2460924/Dermatologists Patti Farris, MD and Ted Lain, MD will kick off the Science of Skincare Summit November 6 at JW Marriott Essex House in New York City. The one-day event is dedicted to education on skincare for medical and aesthetic professionals in all specialties, with content delivered
- Incyte's Opzelura is First Topical JAK Inhibitor Approved in UShttps://practicaldermatology.com/news/incyts-opzelura-is-first-topical-jak-inhibitor-approved-in-us/2460919/Opzelura™ (ruxolitinib) cream from Incyte is now the first and only topical formulation of a JAK inhibitor approved in the United States. FDA approved Opzelura for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis
- DermWire Special Report: JAK Inhibitors in Dermatologyhttps://practicaldermatology.com/news/dermwire-special-report-jak-inhibitors-in-dermatology/2460916/By Denise Mann, Editor at Large Lots of hope is pinned on Janus kinase (JAK) inhibitors for the treatment of atopic dermatitis (AD), alopecia areata, vitiligo, plus other skin diseases, and the pipeline is full. Will the recent FDA decision to expand the boxed w
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adult
- OncoBeta Launches Study of Rhenium-SCT for Skin Cancerhttps://practicaldermatology.com/news/oncobeta-launches-study-of-rhenium-sct-for-skin-cancer/2460909/OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properti
- Study Highlights Severe AD, Depression Linkhttps://practicaldermatology.com/news/study-highlights-severe-ad-depression-link/2460907/Severe atopic dermatitis (AD) travels with depression, a new study shows. In a study of 11, 181 kids, severe AD was associated with an approximately 2-fold increase in the likelihood of symptoms of depression and internalizing symptoms across childhood, compared to eczema-free kids.&nbs